co-corresponding authors Character count (excluding references and materials and methods): 26671 GRAPHICAL ABSTRACT HIGHLIGHTS • E2F1 exerts a non transcriptional pro-apoptotic function at the mitochondria • E2F1 interacts with BCL-xL • E2F1 negatively regulates BCL-xL mobility • BCL-xL mobility is required for efficient BAK dependent cell death inhibition Running title: E2F1-BCL-xL interaction triggers apoptosis Short summary: Vuillier et al. highlight that E2F1 interacts with BCL-xL, independently from its BH3 binding groove, and decreases the subcellular mobility of BCL-xL. This interferes with its ability to inhibit mitochondrial outer membrane permeabilisation and accounts for transcription independent E2F1 induced apoptosis.
INTRODUCTION
Major tumor suppressor pathways, such as those relying on p53 or pRB/E2F1, promote pro-apoptotic signals that ultimately converge on Mitochondrial Outer Membrane Permeabilization (MOMP) [1] . BCL-2 (Bcell lymphoma/leukemia-2) family proteins are critical regulators of this process [2] [3] [4] . They are classified into three functionally distinct subgroups depending on their BCL-2 homology (BH) domain composition: multidomain anti-apoptotic proteins (BCL-xL, BCL-2, MCL-1…) oppose multidomain pro-apoptotic proteins (BAX, BAK) and their upstream effectors the BH3-only pro-apoptotic members (BAD, BIM, BID, NOXA, PUMA…) [5] . They do so in great part by engaging in a network of physical interactions, in which the BH3 domain of pro-apoptotic proteins is bound to the hydrophobic groove at the surface of anti-apoptotic proteins.
The balance between these different interactions determines whether or not MOMP occurs due to BAX/BAK oligomerization in mitochondrial membranes.
Changes in BCL-2 protein complexes that lead to MOMP in response to tumor suppression have been extensively described. Not only p53 transcriptionally regulates the expression of BH3-only proteins but it also acts through a non transcriptional effect: it indeed localizes to mitochondria [6] where it can interact with antiapoptotic BCL-2 proteins [7] or with BAX to directly activate it [8] . Therefore p53 exerts a widespread effect on mitochondrial apoptotic priming by impacting, in many ways, on the composition and assembly of the BCL-2 network [9] . Several BCL-2 proteins including BAK and BCL-xL localize preferentially at intracellular membranes (especially in the outer mitochondrial membrane) due to a hydrophobic C-terminal anchor [10] .
The current view is that competence to die can be inferred by snapshot analysis of the state of the BCL-2 network at mitochondria [11] . However, recent data have highlighted that more dynamic features may also intervene. At a whole cell level, BAX, BAK and BCL-xL are not only targeted to mitochondria but their outer membrane associated and integral forms are also shuttled back (« retrotranslocated ») at varying rates [12] .
Retrotranslocation of pro-apoptotic proteins protects from cell death [13] [14] [15] . In contrast, the mechanisms of BCL-xL retrotranslocation and its impact on MOMP onset are not yet completely understood.
E2F1 is the main pro-apoptotic effector of the pRB regulated tumor suppressor pathway. It was described to promote p53 dependent and independent apoptosis in response to either oncogenic stress or DNA damage [1] . E2F1 is recognized to mainly function as a transcription factor, inducing the expression of numerous pro-apoptotic actors, including some BH3-only proteins such as PUMA and BIM. Its transcriptional activity is negatively regulated by pRB in most cases, even though positive modulation was reported upon genotoxic and apoptotic stress [16, 17] . Because some reports hinted that E2F1 might also promote apoptosis by transcription independent mechanisms [18, 19] , we herein investigated whether it might exert a direct effect on the mitochondrial BCL-2 network, as was reported for p53 and for its binding partner pRB [7] ; [20] . We herein show that E2F1 physically interacts with BCL-xL and that it inhibits BCL-xL localization dynamics, which we establish here as critical for negative regulation of MOMP.
RESULTS & DISCUSSION
E2F1 pro-apoptotic activity relies on its stabilization at the protein level in response to cell death stimuli, such as DNA damage, resulting in numerous post-translational modifications [17] . Consistent with this, treatment of pRB deficient, p53-null Saos-2 cells with the genotoxic agent etoposide, at a concentration that induced apoptosis, enhanced E2F1 expression ( Fig 1A) . E2F1 contributed to cell death induction, since down regulation of its expression by siRNA significantly decreased etoposide induced cell death rates ( Fig   1B) . Subcellular fractionation Saos-2 cells ( Fig 1C) and of other cell types ( Fig EV1A) , based on differential centrifugations, revealed the presence of endogenous E2F1 in the heavy membrane fraction that includes mitochondrial and reticulum endoplasmic markers. Mitochondrial fractions with reduced endoplasmic reticulum markers obtained by a second approach based on magnetically labeled anti-TOM22 antibody showed enriched E2F-1, further highlighting its mitochondrial localization ( Fig 1C) .
We investigated whether E2F1 would contribute to apoptosis when localized at intracellular membranes, and specifically at mitochondria. We engineered a mitochondrial targeted, GFP-fused wild type E2F1 (GFP-E2F1, hereinafter named wt form) to which was fused the mitochondrial targeting sequence of ornithine carbamoyltransferase (OTC-GFP-E2F1, hereinafter named OTC form), using a strategy previously used to investigate the mitochondrial effects of p53 and pRB [6, 20] (Fig EV1B and Appendix Fig S1A) .
Specific mitochondrial targeting of OTC-GFP-E2F1 was confirmed by fluorescence microscopy ( Fig EV1C) .
We investigated pRB and p53 independent biological effects of mitochondrial targeted E2F1 by transient transfection of Saos-2 cells followed by investigation of GFP positive cells. As shown in figure 1D, enhanced expression of either wt or OTC forms was sufficient per se to trigger cell death. Importantly, both E2F1 forms sensitized Saos-2 cells to etoposide-induced cell death, strongly arguing that mitochondrial E2F1 potently contributes to cell death onset ( Fig 1D) . As previously published [6] , targeting GFP to mitochondria using OTC did not induce cell death ( Fig EV1D) . Ectopic expression of wt or OTC E2F1 forms induced caspase 3 activation and triggered caspase-dependent cell death since the pan-caspase inhibitor Q-VD-OPh completely protected cells ( Fig EV2A-B ). To directly investigate whether enhanced E2F1 expression triggers MOMP, we used the reporter breast cancer cell line MDA-MB231 that stably expresses an OMI red fluorescent fusion protein which is degraded by the proteasome when released from mitochondria following MOMP [21] ( Fig EV2C) . Quantitative assays by cytometry based on red fluorescence intensity of mitochondria allowed us to discriminate, among GFP-positive cells, intact cells from cells that underwent MOMP ( Fig EV2D) . Both wt and OTC forms triggered MOMP (as detected by a decrease in red fluorescence intensity of mitochondria) in these cells and annexin V staining ( Fig 1E and EV2E ).
As expected, transient transfection of OTC-GFP-E2F1 had no detectable effect on mRNA expression of E2F1 canonical pro-apoptotic transcriptional targets such as TP73, PUMA/BBC3 or BIM/BCL2L11, whose expression was induced by GFP-E2F1 in control experiments ( Fig EV2F) . In addition, it had no impact on HRK expression, which was reportedly induced by wt E2F1, via the indirect inhibition of a repressor complex [22] . To further substantiate that the apoptotic effects of mitochondrial E2F1 reported above ensue, at least in part, from transcription independent mechanisms, we used GFP-fused E2F1 E132 (named E132 form), a DNA binding defective mutant ( Fig EV1B and Appendix Fig S1A) [23] . This E2F1 transcription deficient form induced MOMP and apoptosis by itself and it sensitized Saos-2 cells to etoposide treatment ( Fig 1D-E) .
Likewise, a mitochondrial targeted transcription deficient E2F1 mutant (OTC-GFP-E132) also induced apoptosis upon overexpression ( Fig EV1D) .
Down regulation of BAK and/or BAX expression by RNA interference showed that death induced by wt and OTC forms relied preferentially on BAK in Saos-2 cells (Fig 2A and Appendix Fig S1B) . This was consistent with the identities of anti-apoptotic proteins that prevented cell death induced by either form of E2F-1: ectopic BCL-xL and MCL-1 but not BCL-2 (which does not to modulate BAK dependent cell death, most likely as a result from its lack of interaction with this pro-apoptotic protein) promoted survival ( Fig 2B and Appendix Fig S1C) . BH3 binding activity was required for BCL-xL to inhibit E2F1-induced cell death, since the BCL-xL R139D mutant, whose BH3 binding is impaired [24] (see also below), did not protect cells in the same settings. Moreover, treatment with the BH3 mimetic inhibitor WEHI-539 (which specifically targets BCL-xL) reverted the protection afforded by overexpressed BCL-xL against E2F1 induced cell death ( Fig   2B) . Consistent with above data, both E2F1 forms (and the E132 form) drastically enhanced the proapoptotic effects of ectopically expressed BAK ( Fig 2C, EV3 and Appendix Fig S1D) . Notably, we also observed a similar sensitizing effect of wt and OTC fused E2F1 upon overexpression of BAX and of the upstream activators, the BH3-only proteins BIM, PUMA and truncated BID (tBID) ( Fig 2C and Appendix Fig   S1D) . Thus, although our data put forth a preferential link between E2F1 and BAK, this may be not exclusive and BAX may contribute under certain circumstances.
We then investigated whether the non-transcriptional pro-apoptotic impact of E2F1 on BCL-xLregulated BAK-mediated MOMP relied on a molecular interaction between E2F1 and BCL-xL, which both localize at intracellular membranes and at the mitochondria in particular ( Fig 1B and EV1A ). As shown in figure 3A, E2F1 co-immunoprecipitated with BCL-xL in lysates from Saos-2 cells. Importantly, this interaction was detected in numerous other cell lines independently from their pRB and p53 status ( Fig 3A and EV4A ).
Bioluminescence resonance energy transfer (BRET) assays confirmed a specific proximity between Renilla
Luciferase fused to E2F1 (RLuc-E2F1) and YFP-BCL-xL at a whole cell level ( Fig 3B) . In sharp contrast to these observations, we could not detect any BRET signals between E2F1 and BAK by BRET experiments ( Fig EV4B) . Moreover, pull-down assays using recombinant GST fused E2F1 [25] and recombinant soluble BCL-xL demonstrated a direct interaction between both proteins ( Fig 3C) . We mapped the minimal domain required for E2F1 to interact with BCL-xL to the DNA Binding Domain: fusion proteins containing this region only (DBD, residues 114-191, Fig EV1B and Appendix Fig S1A) showed BRET signals with BCL-xL ( Fig 3B) and pulled down recombinant BCL-xL ( Fig 3C) . E2F1 deleted in its C-terminal end (ΔC, Fig EV1B and Appendix Fig S1A) behaved similarly ( Fig 3B) but a form deleted in its N-terminal end that encompasses the DBD (ΔN, Fig EV1B and Appendix Fig S1A) showed strongly reduced BRET signals and pull-down properties ( Fig 3B and EV4C) . Consistent with the notion that its interaction with BCL-xL contributes to E2F1 pro-apoptotic activity, and in agreement with preceding results [18] , ectopic expression of the DBD and ΔC forms, but not of the ΔN one, induced cell death, MOMP and caspase activity ( Fig 3D and EV4D ).
Arguing for a BH3 binding site independent interaction between E2F1 and BCL-xL, E2F1/BCL-xL coimmunoprecipitations were unaffected by WEHI-539 treatment ( Fig 3A) . Moreover, BRET signals between E2F1 and BCL-xL were left intact by the R139D or G138E R139L I140N substitutions in BCL-xL, which significantly affected BRET signals between BAK and BCL-xL ( Fig EV4E-F) . Notably, recombinant E2F1 had no detectable effect when added to BAK-expressing isolated mitochondria, it did not enhance tBID induced cytochrome C release and it did not derepress BCL-xL inhibition of cytochrome C release under these conditions (J.C. Martinou, personal communications). E2F1 is thus unlikely to function as a competitive inhibitor of BCL-xL to prevent its inhibition of BAK, arguing that it indirectly interferes with BAK/BCL-xL physical and/or functional interactions, as was reported for the DNA binding Domain of p53 [26, 27] . To investigate this further, we explored whether E2F1 would mitigate BCL-xL control over BAK by impacting on a dynamic process, only patent in whole cell assays. Changes in BCL-xL retrotranslocation have been suggested to impact on its anti-apoptotic function [28] . To directly investigate whether BCL-xL shuttling is critical for its ability to inhibit BAK mediated apoptosis, we compared the ability of two variants of BCL-xL (endowed with enhanced retrotranslocation properties) BCL-xL Δ2 and BCL-xL-T BAX [28] to antagonize BAKinduced cell death with that of BCL-xL. These variants more efficiently prevented BAK-induced cell death, indicating that changes in BCL-xL localization dynamics impact on its control over BAK. Apoptosis suppression by BCL-xL required its mitochondrial localization since no protection was observed with the cytosolic BCL-xL A221R variant ( Fig 4A and Appendix Fig S1E) [29] . Of note, BCL-xL Δ2 and BCL-xL-T BAX were not detectably more efficient against BAX-induced cell death than wild type BCL-xL ( Fig 4A) . This could be due to the fact that BAX is intrinsically more mobile than BAK [12] . Alternatively, the cell death rates induced by BAX in these assays may be too low to detect improved protection when BCL-xL retrotranslocation is enhanced.
We then investigated the effects of E2F1 on the subcellular localization dynamics of BCL-xL. To this end, we used MCF-7 cells stably expressing YFP-BCL-xL and performed fluorescence recovery after photobleaching (FRAP) experiments as described in [13] [14] [15] . These cells were transiently transfected with mCherry fused to E2F1 forms (wt, OTC and E132), and we investigated YFP-BCL-xL mobility between the cytosol and mitochondria in red fluorescent cells. We controlled that YFP-fused BCL-xL interacted with wt or E132 forms under these circumstances ( Fig EV5A) . FRAP studies on cells expressing the negative control mCherry revealed that YFP-BCL-xL recovered to about 80% of its initial fluorescence ( Fig 4B) . This indicates that 4/5 of BCL-xL molecules are mobile and that only the 20% remainders are stably associated with the outer mitochondrial membrane. In cells over-expressing E2F1, YFP-BCL-xL only recovered to 60% of its initial fluorescence, indicating a two-fold increase (20% to 40%) of BCL-xL molecules stably associated to the outer mitochondrial membrane compared to controls. We observed the same decrease in recovery rates for the E132 or OTC forms ( Fig 4B) . Similar conclusions were drawn using mouse embryonic fibroblasts stably expressing GFP-BCL-xL ( Fig EV5B) . These experiments support the notion that E2F1, independently from transcription, stabilizes BCL-xL association with mitochondrial membranes, thereby limiting retrotranslocation rates required, as shown above, for full inhibition of BAK.
To the best of our knowledge, our work is the first one to describe how BCL-xL subcellular localization dynamics impact on its ability to inhibit cell death (mediated by BAK in particular), and to define one regulatory element thereof, namely E2F1. Inhibition of BCL-xL retrotranslocation (upon E2F1 accumulation or mutations in its C-terminal end) might erode its anti-apoptotic activity by precluding active shuttling of BCL-xL pro-apoptotic binding partners BAK, but also possibly BAX or BH3 activators, away from their site of oligomerization and action [13, 15, 28] . Alternatively, it might prevent interactions of BCL-xL with nonmitochondrial effectors, involved in its anti-apoptotic function. Interestingly, changes in BCL-xL shuttling also impact on the cell response to BH3 mimetics, since membrane localization of BCL-xL selectively influences its binding to the BH3 domains of apoptotic effectors [29] . Thus, modifications in the respective amounts of mobile versus mitochondrial-stable BCL-xL molecules are functionally relevant and they represent a critical level of regulation of BCL-xL survival function. We show here that these changes can be modulated independently from BCL-xL BH3 binding as E2F1 impacts on BCL-xL localization dynamics while interacting with it at a site that appears different from its BH3 binding one. The reported effect of E2F1 might extend to retrotranslocation of the other inhibitor of BAK, MCL-1 [30] . Of note, another implication of our work is that differences in BCL-xL localization dynamics may be found between cancer versus normal cells due to differences in E2F1 expression and activity [31] . In all cases, it underscores that the BCL-2 regulated apoptotic network has to be considered as a dynamically evolving one, which is influenced by tumor suppressor pathways not only at the level of synthesis rates and protein complex formation but also at the level of shuttling kinetics between subcellular membranes and the cytosol.
MATERIALS AND METHODS

Cell Culture and reagents
Cells lines were obtained from ATCC excepted the HCT116 p21 -/cell line that was kindly provided by Dr Volgenstein. Saos-2 and HCT116 p21-/-were cultured in Mc Coy's 5A; MCF-7 and BT-549 in RPMI 1640 and U251 in DMEM. MCF-7 stably overexpressing YFP-BCL-xL was obtained by transfection with peYFP-BCL-xL and selection with G418. MDA-MB-231 OMI-mCherry cells were selected with puromycine after infection with retroviruses (MOI 3) containing vector coding for human OMI sequence fused to the mCherry sequence. Cells with moderate expression of OMI-mCherry were sorted with the BD-FACS ARIA III sorter. All transfections were performed using Lipofectamine 2000 according to the manufacturer's instructions. Unless indicated otherwise, treatments were used at the following concentrations: 2μM of Wehi-539 (ApexBio), 50μM of Etoposide (Sigma) and 5μM de Q-VD-OPh (R&D System).
Flow cytometry
Apoptosis analysis was evaluated by staining cells with Annexin V-APC (BD Pharmingen) or with anticleaved caspase3-AlexaFluor 647 antibody (9602, Cell Signaling) according to the manufacturer's instructions and performed on FACS Calibur (BD Biosciences) using the CellQuestPro software (Becton-Dickinson). MOMP quantification in MDA-MB231 OMI-mCherry cells was determined by evaluating the mCherry low fluorescence cell percentage using the BD-FACS ARIA III (BD-Biosciences) operated by the DIVA software.
Plasmids
The pcDNA3.1, peYFP-C1 and pRLuc-C1 plasmids were used to express BCL-2 family proteins. YFP-TM BCL-xL contains the 209 to 233 amino acid of BCL-xL. BCL-xL Δ2 and BCL-xL-T BAX alleles were kindly provided by F. Edlich. Human E2F1 and the ΔC, DBD and ΔN encoding sequences were cloned in peGFP-C1, pmCherry-C1, pRLuc-C1 or pGEX-4T1 plasmids to express the GFP, mCherry, RLuc and GST fusion E2F1 proteins, respectively. ΔC, DBD and ΔN sequences lead to the expression of E2F1 amino-acids residues 1-214, 114-191 and 191-437 respectively. The mitochondrial targeting sequence of ornithine carbamoyltransferase (OTC) from Lwtp53 plasmid [6] was cloned in fusion with GFP-and mCherry-E2F1 encoding sequence. L132E N133F point mutations (E132 allele) were introduced by directed mutagenesis.
siRNAs and transfection
The following siRNAs were used: siE2F1 (HSC.RNAI.N005225.10.3), siBAX (ON-TARGETplus BAX siRNA smart pool L-003308-01), siBAK (ON-TARGETplus BAK1 siRNA smart pool L-003305-00), and SiControl (ON-TARGETplus Non-targeting pool D-001810- [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Plasmids and siRNAs were transfected according to manufacturer's instructions (Invitrogen) using Lipofectamine 2000 and Lipofectamine RNAi Max, respectively.
RNA Extraction, reverse Transcription and real-time quantitative qPCR
RNAs were extracted using Nucleospin® RNA (Macherey Nagel). Reverse transcription was performed using Maxima First Strand cDNA Synthesis Kit for qPCR (Thermo Scientific). qPCR was realized on Stratagene Mx3005P thermocycler (Agilent Technologies) using Maxima SYBR Green qPCR Master Mix (2X) ROX kit (Thermo Scientific). Heavy membrane fractionation and mitochondria purification MCF7 and HeLa heavy membranes fraction were prepared by differential centrifugations as described in detail previously [32] . Saos2 subcellular fractionation to isolate heavy membranes fraction was performed using Mitochondria Isolation Kit for Cultured Cells (Thermo Scientific) based on differential centrifugations. Briefly, cells were lysed in the supplied buffer with proteases/phosphatases inhibitor by using a dounce homogenizer. Sequential centrifugation (3x700g 10 min and 12000g 20 min) leads to pellet the heavy membrane fraction. Pellet was resuspended with CHIP buffer and was used for Western blot analysis. A subcellular fraction enriched in intact mitochondria was prepared from Saos2 cells using the MACS Technology and superparamagnetic microbeads conjugated to anti-TOM22 antibody (Mitochondria isolation kit, Miltenyi Biotec). Briefly, cells were homogenized in the supplied lysis buffer by using a dounce homogenizer. Lysate was incubated with anti-TOM22 magnetic beads for 1 hour at 4°C before magnetically separating the mitochondria on the MACS column. The magnetically labeled mitochondria were resuspended with CHIP buffer and was used for Western blot analysis. Total extract was obtained by directly lysing cells in CHIP buffer.
Immunoprecipitation assay
Protein lysates were obtained by lysing cells with PBS-1%CHAPS buffer containing proteases/phosphatases inhibitor and clarification at 13 000g 15 min 4°C. Immunoprecipitation was performed on 500µg of protein lysates incubated with 10µl of anti-BCL-xL or anti-E2F1 antibodies by using the PureProteome™ Protein G Magnetic Beads protocol (Millipore).
Pull-down assay
Recombinant proteins: GST, GST-E2F1, GST-ΔC, GST-DBD and GST-ΔN were produced in E. Coli, prior immobilization on glutathion-sepharose (Amersham Biosciences), followed by incubation with 100ng of recombinant BCL-xL (Biorbyt). Interactions were evaluated by immunoblotting anti-BCL-xL ([E18] Ab32370) or anti-GST (Rockland).
BRET saturation curves assays
BRET experiments were performed as described in [29] . Briefly, cells were plated in 12-well plates and transfected with increasing amounts (50 to 1500 ng/well) of plasmids coding for a BRET acceptor (YFP-BCL- 
Statistical Analysis
Unpaired student's t test was used for statistical analysis with GraphPad Prism 5.0 Software. Errors bars represent standard errors of mean (SEM). The symbols correspond to a P-value inferior to *0.05, **0.01, ***0.001 and **** 0.0001.
The authors declare that they have no conflict of interest. OTC-GFP-E2F1 for 48h before apoptosis measurement as described in figure 1D. (B) BCL-xL suppresses E2F1-induced apoptosis as a BH3-binding protein. Saos-2 cells were co-transfected with plasmids encoding the indicated anti-apoptotic proteins (BCL-xL or its R139D mutant, BCL-2 or MCL-1) and GFP, GFP-E2F1 or OTC-GFP-E2F1 in a molecular ratio 3:1. 24h later, apoptosis was analyzed as described in figure 1D .
FIGURE LEGENDS
(C)
Mitochondria-targeted E2F1 promotes cell death activity induced by BAK, BAX or BH3-only activators overexpression. Saos-2 cells were co-transfected with the indicated expression vectors and for GFP, GFP-E2F1 or OTC-GFP-E2F1 in a molecular ratio 3:1. 24h later, apoptosis was analyzed as described in figure   1D . The deficient activator PUMA 3A, carrying L141A D146A L148A substitutions in the BH3 domain was used as a negative control. Transcription deficient E2F1 E132 acts synergistically with BAK or BH3-only activator to induce apoptosis.
Saos-2 cells were co-transfected with expression vectors for either BAK or BH3-only activator and GFP or GFP-E132 in a molecular ratio 3:1. 24h later, apoptosis was evaluated as described in figure EV1D . 
